期刊文献+

常见甲状腺疾病与系统免疫炎症指数研究进展 被引量:1

Research Progress of Common Thyroid Diseases and Systemic Immune Inflammation Index
下载PDF
导出
摘要 甲状腺疾病是常见的内分泌系统疾病,常见的甲状腺疾病有甲状腺结节、甲状腺炎、甲状腺功能亢进症、甲状腺功能减退症等。甲状腺肿瘤是一种最常见的内分泌和头颈肿瘤。DTC是恶性肿瘤里最常见的类型,虽发病率高,但早期病人预后好,虽说大部分甲状腺癌预后较好,但颈部淋巴结转移和远处转移依然常见。随着炎症反应和免疫反应在肿瘤的发生、发展的机制越来越清晰,本文就一些免疫因子与常见甲状腺疾病做一综述,为甲状腺肿瘤的良恶性鉴别及甲状腺肿瘤的诊断、预后等提供一些理论参考。 Thyroid disease is a common endocrine system disease. The common thyroid diseases include thy-roid nodules, thyroiditis, Hyperthyroidism, hypothyroidism, etc. Thyroid tumor is the most common endocrine and head and neck tumor. DTC is the most common type of malignant tumor. Although the incidence rate is high, early patients have a good prognosis. Although most thyroid cancers have a good prognosis, neck lymph node metastasis and distant metastasis are still common. As the mechanism of inflammatory response and immune response in the occurrence and development of tumor become clearer and clearer. This article reviews some immune inflammatory factors and common thyroid diseases, and provides some theoretical references for the differentiation of benign and malignant thyroid tumors, diagnosis and prognosis of thyroid tumors.
作者 宋晨 赵海宁
出处 《临床医学进展》 2022年第5期4700-4704,共5页 Advances in Clinical Medicine
  • 相关文献

参考文献5

二级参考文献40

  • 1赵跃,郭永刚,孙甲甲,刘春蓉,周广磊,黄景昊,王宁,吴凤云.术前SII、NLR、PLR在分化型甲状腺癌中的诊断价值分析[J].兰州大学学报(医学版),2018,0(6):50-56. 被引量:10
  • 2中国甲状腺疾病诊治指南——甲状腺功能亢进症[J].中华内科杂志,2007,46(10):876-882. 被引量:856
  • 3Poveda A, Gonzalez-Martin A. Multimodality treatment in locore-gional gynecological cancer: cervical cancer treatment update[J]. Ann Oncol, 2008, 19(Suppl 7):vii70-76. 被引量:1
  • 4Gianni L, Pienkowski T, Im YH, et al. Efficacy and safety of neoad-juvant pertuzumab and trastuzumab in women with locally ad-vanced, inflammatory, or early HER2-positive breast cancer (Neo-Sphere): a randomised multicentre, open-label, phase 2 trial[J]. Lan-cet Oncol, 2012, 13(1):25-32. 被引量:1
  • 5Raungkaewmanee S, Tangjitgamol S, Manusirivithaya S, et al. Platelet to lymphocyte ratio as a prognostic factor for epithelial ovarian cancer [J]. J Gynecol Oncol, 2012, 23(4):265-273. 被引量:1
  • 6Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of an-ti-PD-L1 antibody in patients with advanced cancer[J]. N Engl J Med, 2012, 366(26):2455-2465. 被引量:1
  • 7Voloshin T, Voest EE, Shaked Y. The host immunological response to cancer therapy: An emerging concept in tumor biology[J]. Exp Cell Res, 2013, 319(11):1687-1695. 被引量:1
  • 8Majeti BK, Lee JH, Simmons BH, et al. VEGF is an important me-diator of tumor angiogenesis in malignant lesions in a genetically en-gineered mouse model of lung adenocarcinoma[J]. BMC Cancer, 2013, 13(1):213. 被引量:1
  • 9Unal D, Eroglu C, Kurtul N, et al. Are neutrophil/lymphocyte and platelet/lymphocyte rates in patients with non-small cell lung can-cer associated with treatment response and prognosis[J]? Asian Pac J Cancer Prev, 2013, 14(9):5237-5242. 被引量:1
  • 10Stone RL, Nick AM, McNeish IA, et al. Paraneoplastic thrombocy-tosis in ovarian cancer[J]. N Engl J Med, 2012,366(7):610-618. 被引量:1

共引文献59

同被引文献11

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部